

Implementing a digital clinical decision support tool for side effects of antipsychotics: a qualitative focus group study

Catherine Henshall (corresponding author), Oxford Brookes University, Faculty of Health and Life Sciences, Jack Straws Lane, Oxford, Oxfordshire OX3 0FL chenshall@brookes.ac.uk Tel: 07768 918298

Andrea Cipriani, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK;
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK

David Ruvolo, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK

Orla MacDonald

Leona Wolters, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK

Ivan Koychev, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK

Word count: 3277

ABSTRACT

Background

Medical algorithms combining the latest evidence about medication side-effects with similar efficacy profiles provide opportunities for improved shared clinician-patient decision-making when initiating therapy. We designed a clinical decision support tool that incorporated the latest evidence regarding antipsychotic side-effects. The tool allowed patients to select one side-effect commonly associated with antipsychotics that they wished to avoid; the tool then provided a list of suggested medications and ones to avoid.

Objective

To explore qualitatively the acceptability and usefulness of the clinical decision support tool from the perspectives of patients and psychiatrists.

Methods

This qualitative study took place at a mental health and community hospital in Oxford, United Kingdom, in 2018. Four patients/carers and four psychiatrists were recruited to two focus groups to explore their perceptions of the tool. Data was thematically analysed.

Findings

The main themes to emerge relating to the clinical decision support tool were 'prescribing preferences and practices', 'consideration and awareness of side-effects', 'app content, layout and accessibility', 'influence on clinical practice' and 'role in decision-making'.

Conclusions

Findings demonstrated a high degree of acceptability and potential usability of the clinical decision support tool for patients and psychiatrists. A proof-of-concept clinical study will incorporate the recommendations produced from the findings into the tool's design.

Clinical Implications

Digital clinical decision support tools provide opportunities for the most up-to-date information on medication side-effects to be used as the basis for shared clinician-patient decision making. This has the potential to improve adherence to psychiatric medication, with benefits to clinical outcomes and healthcare resourcing.

Summary box:
What is already known about this subject? 3-4 bullet points
What are the new findings? 3-4 bullet points
How might it impact on clinical practice in the foreseeable future?

BACKGROUND

The global prevalence and burden of psychiatric disorders worldwide is rising, yet this is not reflected by the slow pace of progress in treatment development[1]. It is imperative that all available scientific information is considered when making treatment decisions to improve patient outcomes and clinical care. *Personalised (or precision) medicine* provides patients with customised interventions that are likely to be effective, whilst having tolerable side-effect profiles[2], often informed through the development of medical algorithms[3]. Clinical decision support tools (CDSTs) are innovative technologies that can provide continuously updated information about medications to promote shared decision-making between patients and clinicians[4].

CDSTs have the potential to improve adherence to medical therapies through patient decision-making, empowerment and improved awareness of potential side-effects[5]. Negative experiences of side-effects are a major reason for treatment discontinuation among patients, with up to 50% of patients reporting this as a reason for non-compliance[6]. In addition, having past experience of side-effects can lead to a stronger aversion to future antipsychotic treatments, resulting in poorer adherence[7].

Studies using non-digital CDSTs that aim to improve shared decision-making in antipsychotic prescribing have demonstrated improved perceived involvement and disease knowledge, which is associated with better clinical outcomes[8]. However, a key feature missing in existing treatment algorithms is their ability to dynamically incorporate patients' views in the decision-making process. We wanted to fill this gap and create a more intuitive, patient-friendly and web-based application for comparing antipsychotics in terms of their likelihood of causing specific side effects.

Our CDST

Our computer-based CDST, “In Control of Effects”, was developed by RStudio v.1.1.463[9] using the package Shiny[10]. The production version of the application is hosted on a Digital Ocean Ubuntu 16.0.4.4 x 64 server using Shiny Server Open Source (v.1.5.9.923). The CDST is an application, which is structured into three screens: instructions, side-effect selection and results (See Figures 1 and 2 for example of the latter two screens). The user navigates between the individual pages using a series of clicks. The initial section presents instructions for using the application and emphasizes that the purpose of the CDST is to act as a decision support tool only in the context of a discussion between the patient and the treating clinician. In the second section, participants are presented with four side effects (weight gain, sexual dysfunction, irregular heartbeat and stiffness/tremor) and are asked to select one side-effect they would like to avoid. The side effects were chosen on the basis of data availability from a recent meta-analysis [11]. Each side-effect is accompanied by a short explanation of that side-effect in lay language, which can be accessed by tapping or clicking a toggle to reveal content. When a participant submits their responses, they are led to the results section and are shown a list of the top three medication recommendations, as well as the top three antipsychotics to avoid.

Which side effect would you like to avoid?

Tap the name of the side effect that you would like to avoid. You may select one side effect. Tap the plus + for more information. Selected items will change color. When you are ready, press the submit button. Press the info button to read through the instructions.

✓

Weight Gain

×

Some antipsychotic medications may lead you to put on weight through an increase in appetite and a recurring feeling of hunger.

Irregular Heartbeat

+

Sexual Dysfunction

+

Stiffness & Tremor

+

Info

Submit

Figure 1. Side effects of the In Control of Effects (ICE) application. On this screen participants choose from one of four side effects whereby clicking on the cross next to each side effect reveals a brief description of it.

Results

Based on the selections you've made, here are the results. The 'recommended' medication list have a low likelihood of causing the side effect that you selected. The 'avoid' medication list have a high likelihood of causing of the side effect that you selected.

Recommended

- ✓

1. Zotepine
- ✓

2. Chlorpromazine
- ✓

3. Olanzapine

Avoid

- ⚠

1. Triflupromazine
- ⚠

2. Trifluoperidol
- ⚠

3. Trifluoperazine

You can either press the 'Restart' button to select a different side effect or press the 'Exit' button to exit the web app.

Figure 2. Results screen (of the In Control of Effects (ICE) application). On this page three preferred options are suggested and three medications are singled out as ones to avoid. In this example 'Weight Gain' had been selected as the side effect to avoid.

The database used to rank the antipsychotics in terms of specific side-effects was based on the results of a network meta-analysis of published and unpublished randomised controlled trials[11]. User input was coded as binary (0 = not selected, 1 = selected), and then used to generate a new score per medication by averaging the prevalence of the side-effects per drug weighted to the preferences of the participant. A lower score indicates a decreased likelihood of experiencing the side-effects selected (i.e. more favourable) relative to the other antipsychotics in the dataset, whereas drugs with a high score have an increased risk of producing the side-effect.

In this study we aimed to qualitatively explore the acceptability and usefulness of the CDST from the perspectives of patients, carers and psychiatrists.

OBJECTIVE

We aimed to explore psychiatrist, patient and carers' views on the acceptability and usefulness of our newly developed CDST in relation to its use as a shared decision-making tool between clinicians and patients. Our intention was to use the study findings to modify and make further improvements to the CDST, before piloting it in a real-world clinical setting.

METHODS

Participants and setting

Two focus groups took place at the Warneford Hospital, Oxford Health NHS Foundation Trust in Oxford, United Kingdom, between June and August 2018 (one focus group with psychiatrists and one with patients, to allow both user groups to speak freely without any reticence and to promote constructive discussions). Ethical approvals were not required due to the project being classed as Quality Improvement by Oxford Health NHS Foundation Trust; however written informed consent was taken from each participant prior to their participation.

The focus groups aimed to identify how acceptable the CDST was to psychiatrists, patients and carers in terms of its layout, content and applicability to the clinical setting. Focus groups were deemed more appropriate than individual interviews as they enabled collective discussion and debate between users with multiple perspectives.

Access, Recruitment and Sampling

Psychiatrists were recruited to the first focus group through the Thames Valley Higher Trainee in General Adult and Old Age Psychiatry Forum. Those who expressed an interest in participating were provided with a participant information sheet via email and were asked to contact the researchers.

The second focus group was undertaken with patients and carers, who were identified via the Patient and Public Involvement Lead for Oxford Health NHS Foundation Trust, who posted an advertisement for the focus group via a number of forums including local patient and public involvement groups, Trust intranet, patient/research websites, social media outlets and through local mental health partnerships and charities. To be eligible for study inclusion participants had to have a mental health diagnosis requiring treatment with an antipsychotic (currently or in the past). A convenience sampling strategy was implemented for both focus groups (i.e. all those able to attend were invited). Information and guidance to run the focus groups were found on the Involve website[12]. The focus groups began with a researcher (LW) providing a short, interactive, visual demonstration of the CDST, before answering questions relating to it. Each focus group lasted one

hour and was informed by a topic guide that covered themes relating to the CDST's layout, content, applicability, usability and acceptability (Table 1). The focus groups were moderated and facilitated by at least two researchers from the team: CH and LW led the psychiatrists' focus group, whilst CH, LW and IK led the patients/carers' one. Focus groups were digitally recorded and then transcribed by a local transcription service. All identifying participant details were anonymised during transcription and the focus group recordings were destroyed.

Table 1: Examples of questions from topic guide used to undertake focus groups with psychiatrists and patients/carers

<ul style="list-style-type: none"> • Can you tell me what you think about the layout of the CDST? • Can you tell me what you like/do not like about the CDST? • Can you think of any ways the CDST could be improved upon (structure, format etc..)? • Can you think of anything that should be added/removed to the app to improve it? • Are you aware of any other example of electronic decision-making tools? <p>Specific to psychiatrists</p> <ul style="list-style-type: none"> • What are the strengths and weaknesses of using this app in clinical practice? • Do you think the CDST may have any impact on the doctor-patient relationship (i.e. too lengthy in set up, or too impersonal)? • Are there any particular patient groups or circumstances where this tool can be particularly useful (or unhelpful)? • Are there any advantages/disadvantages of using this CDST in clinical practice? • Are there any "links/shortcuts" that you would like to have on your iPad/computer, when using the app (such as a link to the BNF, or a list of contraindication/interactions)? • How do you feel using an electronic tool compares to using more traditional methods in clinics (e.g. book-based guidelines)? <p>Specific to patients/carers</p> <ul style="list-style-type: none"> • Are there any advantages/disadvantages of using this CDST in your clinic appointment? • How do you think other patients and carers will respond to the CDST? • Do you think it may have any impact on your relationship with the doctor (i.e. too lengthy in set up, or too impersonal)? • How do you feel when your doctor would use an electronic tool compared to using more traditional methods, such as a book, in your clinic appointment?

Data Analysis

Data was thematically analysed and managed using the Framework method[13]. A researcher (CH) coded the transcripts and, using the constant comparative method[14], any similarities and differences in perspectives between psychiatrists and patients/carers were established. Transcript

data were inserted into a Framework matrix to enable data ordering and synthesis[13]; this enabled within and across case data analysis from both focus groups. Through this process, relevant themes pertaining to participants' views and perspectives on the CDST emerged from the dataset. These emerging themes were discussed within the research team (CH, LW, IK) as a method of triangulation to verify the study findings.

FINDINGS

Summary of Main Themes

Eight participants attended the focus groups (four psychiatrists and four patients/carers). The four psychiatrists were relatively young (mean age: 38 years, range 30-45) and had been practicing clinically for eight years on average. They all regularly treated inpatients and outpatients who needed antipsychotics prescribing. The average age of the patients/carers was 60 years (range 53-67). Patients/carers had a range of mental health diagnoses, including bipolar disorder, anxiety and depression, and all had experience of taking, or caring for someone taking, antipsychotic medication. Summary characteristics are presented in Table 2. The main themes to emerge from the dataset about the CDST were 'prescribing preferences and practices', 'consideration and awareness of side-effects', 'app content, layout and accessibility', 'influence on clinical practice' and 'role in decision-making'.

Table 2: Summary characteristics of psychiatrists and patients/carers

	Psychiatrist n=4		Patients/Carers n=4
Age (years)	38 ± 7	Age (years)	59.5 ± 6.1
Years in practice	7.75 ± 2.9	Experience with antipsychotic medication	
		- Currently taking	1
		- Taken in the past	2 ¹
		- Carer	2 ¹
Number of patients seen per month who need antipsychotic medication	11 ± 6	Diagnosis	
		- Depression	2
		- Bipolar disorder	1
		Medication taken	Amitriptyline, Stemetil, Chlorpromazine, Trifluoperazine, Halopirdo

¹One person fulfils the criteria of both groups.

Prescribing preferences and practices

All psychiatrists commented that the CDST would help increase their awareness and consideration of a wide scope of medications. They felt this was necessary as they admitted that they generally prescribed a limited selection of drugs, based on anecdotal evidence and simplistic cost-effectiveness considerations. However, a lack of familiarity with some of the CDST's recommended medications, and the fact that some were not licensed for use, provided a deterrent.

'Bar Loxapine, which I've seen once, I've never seen any of the others...That would not be helpful for me.' Psychiatrist 2

Patients and carers commented that the CDST could provide a useful starting point for discussions with their doctor about medication preferences, as it ranked medications in terms of suitability to their own preferences.

'I want to have the greatest chance of success on proven clinical stuff so far...But number one would be the one to start with...If it didn't work, then try number two.' Patient/carer 1

Psychiatrists felt that the comprehensive, up to date and evidence-based information on the CDST would increase their prescribing confidence with new medications. However, contextual factors relating to patients' physical and social health, were noted as also influencing psychiatrists' prescribing practices, something which was not factored for by the CDST. Despite this, psychiatrists felt that it could be a useful base for considering medication options with patients.

'You're much more constrained in the antipsychotic you could give each patient...But it could still be used as a launch pad for those types of discussions.' Psychiatrist 4

Consideration and awareness of side-effects

Psychiatrists commented that doctors often make prescribing choices based on efficacy, without considering sufficiently the impact of potential side-effects. Conversely, patients/carers stated that a drug's side-effect profile would substantially influence their likelihood of compliance and that this information was crucial. All participants felt that information relating to a patient's age and co-morbidities on drug efficacy, mode and frequency of administration and potential side-effect severity should be included within CDST. They also felt it should provide a balanced level of information on the most common side-effects of each drug listed, to allow patients to decide how acceptable these side-effects were.

'[Otherwise] you'd be selecting a drug without necessarily thinking about what the other side-effects could be...And then you get prescribed one that actually has another side-effect that you don't want at all, but it wasn't even mentioned.' Patient/Carer 1

Patients/carers felt that receiving information about the likelihood of experiencing a side-effect and its subsequent severity would enable them to weigh up the risk versus benefit ratio, informing their decision-making.

'Weight gain in 3% of the population... You'd probably say, I'll be okay with that even if you are already overweight. Whereas if it's 50% of patients that use this put on weight, you'll probably think, then I'm not so sure.' Patient/Carer 1

App content, layout and accessibility

Visuals

The CDST was described as 'attractive' and 'readable' by most participants, with its blue and green features perceived as 'healthcare colours'. However, some visual design improvements were suggested, including incorporating the word 'decision-aid' into the name of the CDST, increasing the font size, providing bite-size sections or drop-down lists of content and visually depicting the highest ranked medications and their side effect profiles. Most participants wanted percentages displayed as they were easily understandable.

'I think everybody understands if you say 100%...Because if it was a 50% chance of weight gain, that's a fair chance you're getting it. It's a toss of a coin. Whereas if it was just 10%, you might not, I suppose.' Patient/Carer 1

Interactivity

All participants felt the tool was simple and straightforward to use, whether on a mobile or a laptop, and that it was easy to navigate.

'I'm all for simplicity and I found it... I'm a technophobe. I've got my smartphone. It's not set up yet.

But I used that smartphone with no problem at all.' Patient/Carer 4

The CDST was seen as a means of stimulating, rather than replacing, discussion, avoiding paternalism by promoting shared decision-making between doctors and patients. However, a couple of psychiatrists felt the CDST would be more accessible if it was downloadable, rather than requiring WiFi access. Most participants felt it would be most useful as an adjunct to other information sources such as the internet, leaflets and face-to-face discussions.

'It's part of an armoury of enabling patients to be involved in their treatment decisions.' Psychiatrist

4

One patient/carers suggested that a supplementary app website would be helpful, with patients being directed to it after their introduction to the CDST during their consultation with their doctor.

'If you've got it on a website...Having done it in the office with you... They can go away if they haven't made the decision and play with it some more, which might be useful.' Patient/Carer 4

Influence on clinical practice

All psychiatrists felt that the CDST could be utilised clinically, both in cases of first-episode psychosis and for long-term service-users, as a monitoring and review tool. They felt that the more they used the CDST, the more likely it would be to change their clinical practice.

'I imagine that if it is something that is very routinely used ... I'd like to think somebody like me would make changes over time. Not within a week, two weeks, but maybe over a year.' Psychiatrist 2

Some psychiatrists felt there was a danger that the CDST could increase paternalism if the drugs listed on it were not perceived as clinically relevant, as this could result in doctors overriding patient preferences if they felt that the patient's drug of choice was not credible. However, others commented that it could help educate doctors about the efficacy and side-effect profile of relatively unknown medications, increasing the likelihood of them being integrated into practice.

'Certainly, there's things there which I'm sure I'm going to learn that I will integrate into my practice as I go along. If there is a link for the evidence, that could be very helpful, actually, because every evidence needs to be looked at and can be discussed, debated, argued against.' Psychiatrist 2

Psychiatrists felt the CDST was unsuitable for use in Primary Care as general practitioners may lack the knowledge or experience to prescribe antipsychotics. However, some patients/carers felt it could be used by general practitioners as a referral tool or to help monitor psychiatric patients in primary care, especially if patients were unable to see their psychiatrist immediately due to long waiting lists.

'You'd see a doctor a lot quicker than you'd see a psychiatrist if you're feeling awful. Wouldn't you want to see your doctor pretty quickly for a potential change of drug that might assist you, rather than wait?' Patient/Carer 1

Role in decision-making

All participants felt patients should be involved in decision-making around medication choices and that the CDST promoted informed choice, patient engagement and discussion around potential trade-offs between side-effect tolerability and drug efficacy.

'This fulfils, or could fulfil, a valuable purpose in getting a bit more buy-in to treatment from patients. Because the drug has come out of their preferences, and not you saying, you should go on this.'

Psychiatrist 4

Regarding compliance, all psychiatrists felt that patients would be more likely to comply with their medications after engaging with the decision-making process via the CDST. However, some patients/carers felt that regular face-to-face doctor/patient discussions were required to avoid patients feeling pressured into making decisions using the CDST alone. All participants acknowledged the complexity of the decision-making process and felt the CDST was a small piece of the whole picture.

'The app... It's a good start...Sometimes decision-making is more complex. You as a clinician have to take more into consideration rather than just a few clicks, side effects' Psychiatrist 1

DISCUSSION

The focus group findings have demonstrated the potential of the CDST to increase clinician and patient knowledge, confidence and awareness of a wide range of antipsychotics, as well as providing a forum for enhancing collaborative patient-clinician decision-making. However, a number of issues were identified, which, if addressed appropriately, could substantially improve the acceptability and credibility of the tool.

The inclusion in the tool of any antipsychotic studied in a randomised controlled trial (either licensed or unlicensed, commissioned or non-commissioned) was viewed by psychiatrists' as unnecessary and unhelpful. It is important therefore, that the list of recommended medications on the CDST are carefully reviewed and adapted to ensure that only medications that are available in a specific clinical context are included[15]. This will serve to increase the usability, acceptability and relevance of the CDST for both patients and clinicians, whilst avoiding potential disappointment or frustration that seemingly suitable medications are unattainable.

Participants appreciated the CDST's ability to rank medications in terms of suitability, with regard to their side-effect profiles, but commented that they would like more information about the likelihood of experiencing a side-effect from one medication compared to another. This is something which warrants careful consideration when making further modifications to the CDST[16]. Whilst the visual ranking of different drugs can be a useful discussion aid, care must be taken to ensure that the information on display is not misleading. For example, a lack of clarity around whether the data presented ranks drugs against one another or versus placebo is possible, as is confusion around whether the relative or absolute risk is being presented. This could lead to clinicians and patients selecting drugs based on evidence that has been misinterpreted, raising ethical issues around informed choice[17]. Care must be taken to ensure that the data are based on the best available evidence and presented in a transparent way, whilst remaining accessible and easily understandable to patients and clinicians alike[18].

In addition, in response to feedback from participants, the CDST could be further modified to increase the number of side-effects displayed so as to provide patients with a realistic overview of the side-effects they are most likely to encounter with different types of medications[19]. This is important, as whilst a patient may express a strong desire not to take a drug that leads to weight gain, if they see that this drug is more likely to cause a number of other side-effects than a slightly

lower ranked (but still efficacious) drug, they may use this information to inform their decision-making, which may in turn affect their subsequent medication compliance.

Any clinical tool should be accessible to the wider patient population and reflect the needs of a variety of patients, including those who are not technologically experienced. This can be achieved not only by ensuring that the information presented is as simple, understandable and easy to navigate as possible, but also by considering the provision of supplementary resources to complement the information provided. Our CDST is intended to be used as an adjunct to, rather than a replacement for, face-to-face clinical discussions[20]. This message must be clearly conveyed to both patients and clinicians in order to avoid disappointment, communication errors or a breakdown in the clinician-patient relationship, all of which may lead to a reduction in compliance and an increase in patients' dissatisfaction with care.

CLINICAL IMPLICATIONS

The CDST improved participant involvement and knowledge about medications by demonstrating the advantages of a digital solution to guide clinical decision making in real world practice. There is a need for further modifications to be made to the tool to ensure that it meets the preferences and requirements of patients, carers and clinicians. Once these changes are complete, the newly modified CDST will be tested in a pilot acceptability study in a psychiatric outpatient setting, to collect data on how patients and clinicians experience using the CDST and the subsequent impact on patient outcomes. In addition to enhancing informed choice for patients, improving patient-clinician communication and ensuring that clinical prescribing practices in psychiatry are consistent, the digital platform can provide a cost-effective solution to aligning the provided advice with the latest available evidence[21]. This will be an important step in the field of precision medicine in clinical psychiatry.

ACKNOWLEDGEMENTS

The authors would like to thank the patients and carers who agreed to contribute their time and effort into this Public and Patient Involvement project. We would also like to thank Dr Saïk De La Motte, Dr Shayda Khoshnaw, Dr Romanie Dekker and Dr Ed Mitchell for participating in the focus group involving psychiatrists. We acknowledge the support of the Oxford Health NHS Foundation Trust and the Oxford Health NIHR Clinical Research Facility and Biomedical Research Centre.

AUTHOR CONTRIBUTORSHIP

Catherine Henshall prepared the first draft of the manuscript and collated authors' input. Ivan Koychev and David Ruvolo designed and implemented the ICE application with substantial input from Andrea Cipriani. Catherine Henshall, Leona Wolters and Ivan Koychev designed and conducted the focus groups. All authors provided substantial contributions on the data interpretation and revising it critically for important intellectual content. All authors have given final approval of the version to be published and have provided agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

COMPETING INTERESTS AND FUNDING

The authors declare no competing interests and have no associations with commercial entities that provided support for the work reported in the submitted manuscript or with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript. None of the authors have any financial associations involving their spouse or their children under 18 years of age or have any non-financial associations that may be relevant to the submitted manuscript.

DATA SHARING

Data are available upon reasonable request from the corresponding author (CH) (chenshall@brookes.ac.uk) and is comprised of deidentified focus group data from participants.

PATIENT CONSENT AND ETHICAL APPROVAL

Ethical approvals were not required for this study as it was deemed to be a Quality Improvement project by the participating NHS Trust. However, written informed consent was obtained from all participants before they took part in the study.

REFERENCES

1. Harrison PJ, Cipriani A, Harmer CJ et al. Innovative approaches to bipolar disorder and its treatment. *Annals of the New York Academy of Sciences* 2016;1366:76-89.
2. Jameson JL, Longo DL. Precision medicine - personalized, problematic, and promising. *N Engl J Med* 2015;372(23):2229-2234.
3. Trivedi MH, Rush AJ, Crismon ML et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. *Arch Gen Psychiatry* 2004;61(7):669-680.
4. Henshall, C, Marzano L, Smith K et al. A web-based clinical decision tool to support treatment decision-making in psychiatry: a pilot focus group study with clinicians, patients and carers. *BMC Psychiatry* 2017;17:265 doi: 10.1186/s12888-017-1406-z
5. Leucht, S, Heres, S. Epidemiology, Clinical Consequences, and Psychosocial Treatment of Nonadherence in Schizophrenia. *J Clin Psychiatry* 2006;67(suppl 5):3-8
6. Loffler, W, Kilian, R, Toumi, M et al. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. *Pharmacopsychiatry* 2003;36: 105–112
7. Lambert, M, Conus, P, Eide, P et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. *Eur Psychiatry* 2004;19:415-422
8. Hamann, J, Cohen, R, Leucht, S et al. Shared decision making and long-term outcome in schizophrenia treatment. *J Clin Psychiatry*. 2007;68(7):992-7.
9. R Core Team. A language and environment for statistical computing. *R Foundation for Statistical Computing*, Vienna, Austria. 2018;<https://www.R-project.org/>.
10. Chang, W, Cheng, J, Allaire, JJ et al. Shiny: Web Application Framework for R. R package version 1.2.0. 2018;<https://CRAN.R-project.org/package=shiny>

11. Leucht ,S, Leucht, C, Huhn, M et al. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. *Am J Psychiatry*. 2017;174(10):927-942. doi: 10.1176/appi.ajp.2017.16121358.
12. Involve. Focus groups. 2018;<https://www.involve.org.uk/resources/methods/focus-groups>. Accessed March 2018.
13. Gale NK, Heath G, Cameron E et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Method* 2013;13(117).
14. Bryman A: *Social Research Methods*, 3rd edn. Oxford: Oxford University Press; 2008.
15. Connolly, A, Taylor, D. Factors associated with non evidence-based prescribing of antipsychotics. *Ther Adv Psychopharmacol*. 2014;4(6):247-56.doi:10.1177/2045125314540298.
16. Leucht, S, Chaimani, A, Cipriani, A et al. Network meta-analyses should be the highest level of evidence in treatment guidelines. *Eur Arch Psychiatry Clin Neurosci*. 2016;266(6):477-80
17. Pavarini, G, Singh, I. Pragmatic Neuroethics: Lived Experiences as a Source of Moral Knowledge. *Camb Q Healthc Ethics*. 2018;27(4):578-589.doi:10.1017/S0963180118000105
18. Chaimani, A, Salanti, G, Leucht, S et al. Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. *Evid Based Ment Health*. 2017Aug;20(3):88-94.doi:10.1136/eb-2017-102753.
19. Caddy, C, Amit, BH, McCloud, TL et al. Ketamine and other glutamate receptor modulators for depression in adults. *Cochrane Database Syst Rev*. 2015;(9):CD011612.doi:10.1002/14651858.CD011612.pub2.
20. Cipriani, A, Tomlinson, A. Providing the most appropriate care to our individual patients. *Evid Based Ment Health*. 2019;22(1):1-2.doi: 10.1136/ebmental-2019-300080.

21. Austin, CA, Mohottige, D, Sudore, RL et al. Tools to Promote Shared Decision Making in Serious Illness: A Systematic Review. *JAMA Intern Med.* 2015;175(7):1213-21.doi:10.1001/jamainternmed.2015.1679.